Previous 10 | Next 10 |
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotectiv...
Ovid Therapeutics Inc. (OVID) is expected to report $-0.18 for Q3 2023
2023-11-03 16:18:41 ET Ovid Therapeutics ( OVID ) on Friday filed a prospectus for a mixed securities shelf offering of up to $250M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Ovid Therapeutics files for $25...
2023-11-03 10:19:14 ET More on Ovid Therapeutics Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Seeking Alpha’s Quant Rating on Ovid Therapeutics Historica...
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Ga...
2023-10-18 11:05:36 ET More on Ligand Pharmaceuticals, Ovid Therapeutics, etc. Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand: Nothing Exciting Stands Out For further details see: Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid T...
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat Trans...
2023-10-12 17:48:17 ET Gainers: Comtech Telecommunications ( CMTL ) +14% . Relay Therapeutics ( RLAY ) +12% . Ovid Therapeutics ( OVID ) +6% . Groupon ( GRPN ) +5% . Omeros Corporation ( OMER ) +4% . Losers: O...
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at ...
2023-10-04 07:14:23 ET Summary Ovid Therapeutics' OV329 shows promise in early Phase 1 data for treating pharmacoresistant epilepsy, boasting superior pharmacokinetics and safety profiles. Financials are strong with a robust current ratio of 10.1 and 24-month cash runway, but cash...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...